A study funded and conducted in part by the CVS Research Institute found that an expansion of prescription-drug benefits could mean better health outcomes as well as reduced spending.
"Although the United States represents almost half of the biologics market in terms of revenue and volume, biosimilars growth will be fueled by focusing on the emerging markets, by addressing non-consumption and patient inability to pay for high-priced biologics."
"The trouble is that the market is changing much faster than most marketers realize."
Members of the 13-32 age group were less likely to agree that preventive care is the most important factor in staying healthy, compared to Baby Boomers and Gen-Xers.
As patients spend more time in waiting rooms where they are primed to learn about their health, POC promotions are becoming a more essential part of the marketing mix, researchers find.
Complementary solutions to drive growth with health plans as well as pharma clients, companies say.
Despite hurdles of practitioner buy-in and legacy IT, value-based care is on pace to overtake fee-for-service.
An arduous reimbursement process has put a damper on how quickly patients can receive the drug, say analysts, citing KOLs.
Life expectancy for patients cured of advanced HCV similar to healthy peers: study; Ackman takes a $2 billion stake in animal drugmaker Zoetis; Amgen and AstraZeneca report that brodalumab bested Stelara in psoriasis head-to-head.
The CBO projected 13 million enrolled in 2015, but its projections were based before final 2014 numbers were in.
Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.
- Poll shows all ages seek digital health tools
- Survey shows docs overestimate adherence
- Drugmaker shifts sales model to keep pace with formulary decision making
- Oncologist's petition is latest salvo, as drug-pricing issue rises to new prominence
- Global cancer drug market to grow to $111 billion by 2020: report